• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Biospective, Imeka Solutions ink agreement

Biospective, Imeka Solutions ink agreement

May 2, 2014
CenterWatch Staff

Biospective, a provider of imaging and histopathology services, has enhanced its diffusion MRI capabilities through an alliance with Imeka Solutions, a spin-out of the Université de Sherbrooke.

Biospective will incorporate Imeka’s state-of-the-art diffusion image processing into its PIANO and NIGHTWING software packages to provide a solution for analysis of diffusion MRI data for animal and human studies. This will provide sponsors with a one-stop shop for multi-modality MRI (diffusion, anatomical, ASL perfusion, BOLD fMRI, MRS) and PET (Amyloid, FDG) studies. The capacity of Biospective and Imeka to support both preclinical imaging studies and multi-center human clinical trials will facilitate translational studies.   

“The combined strengths of the Biospective and Imeka teams will provide sponsors with a best-in-class solution for diffusion imaging studies across a broad range of therapeutic areas, ranging from neurodevelopmental disorders (autism, ADHD, MPS) to neurodegenerative (Alzheimer’s, Parkinson’s, MS, ALS) and psychiatric (schizophrenia, depression) diseases,” said Alan Evans, Ph.D., founder of Biospective, and James McGill, professor of Neurology and Neurosurgery at the Montreal Neurological Institute.  

Biospective and Imeka already have successfully worked together on several sponsored studies. Further, they recently have engaged in joint R&D activities to analyze diffusion MRI data from several publicly-available databases, including the Alzheimer’s Disease Neuroimaging Initiative (ADNI) and the Parkinson’s Progression Markers Initiative (PPMI). 

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing